These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 30341231)
41. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Younossi ZM; Reyes MJ; Mishra A; Mehta R; Henry L Aliment Pharmacol Ther; 2014 Jan; 39(1):3-14. PubMed ID: 24206433 [TBL] [Abstract][Full Text] [Related]
42. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Carbone LJ; Angus PW; Yeomans ND J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358 [TBL] [Abstract][Full Text] [Related]
43. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Polyzos SA; Kountouras J; Mantzoros CS; Polymerou V; Katsinelos P Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101 [TBL] [Abstract][Full Text] [Related]
44. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Rotman Y; Sanyal AJ Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933 [TBL] [Abstract][Full Text] [Related]
45. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis. Dai X; Wang H; Jing Z; Fu P Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140 [TBL] [Abstract][Full Text] [Related]
46. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. Zaitone SA; Barakat BM; Bilasy SE; Fawzy MS; Abdelaziz EZ; Farag NE Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):587-600. PubMed ID: 25708949 [TBL] [Abstract][Full Text] [Related]
50. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128 [TBL] [Abstract][Full Text] [Related]
51. The effect of ezetimibe on NAFLD. Averna M Atheroscler Suppl; 2015 Feb; 17():27-34. PubMed ID: 25659874 [TBL] [Abstract][Full Text] [Related]
52. Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis. Theodoridis X; Kalopitas G; Vadarlis A; Bakaloudi DR; Gkiourtzis Ν; Dionysopoulos G; Karanika E; Tsekitsidi E; Chourdakis M Pharmacol Ther; 2022 Dec; 240():108294. PubMed ID: 36183848 [TBL] [Abstract][Full Text] [Related]
53. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Faghihzadeh F; Adibi P; Hekmatdoost A Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526 [TBL] [Abstract][Full Text] [Related]
54. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? Musso G; Anty R; Petta S Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094 [TBL] [Abstract][Full Text] [Related]
55. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A; Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076 [TBL] [Abstract][Full Text] [Related]
57. Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis. Jaruvongvanich V; Riangwiwat T; Sanguankeo A; Upala S Saudi J Gastroenterol; 2016 Nov; 22(6):407-414. PubMed ID: 27976635 [TBL] [Abstract][Full Text] [Related]
58. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Cernea S; Cahn A; Raz I Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774 [TBL] [Abstract][Full Text] [Related]
59. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. Makri E; Cholongitas E; Tziomalos K World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393 [TBL] [Abstract][Full Text] [Related]